Scarica l'app Stockscreener
4.17
0.00%
0.00
Dopo l'orario di chiusura:
4.04
-0.13
-3.12%
Aptevo Therapeutics Inc Borsa (APVO) Ultime notizie
APVO Technical Analysis & Stock Price Forecast - Intellectia AI
APVO Forecast, Price Target & Analyst Ratings | APTEVO THERAPEUTICS INC (NASDAQ:APVO) - ChartMill
Update Recap: Can Aptevo Therapeutics Inc sustain its profitabilityMarket Movers & Risk Managed Investment Signals - baoquankhu1.vn
Institution Moves: Will IBEX outperform during market ralliesWeekly Risk Summary & Smart Allocation Stock Tips - baoquankhu1.vn
Nasdaq Moves: What are Aptevo Therapeutics Incs recent SEC filings showing2026 Buyback Activity & Expert Curated Trade Setups - baoquankhu1.vn
Risk Report: Is Aptevo Therapeutics Inc impacted by rising rates2026 Price Targets & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Aptevo’s Mipletamig Shows 86% Clinical Benefit Rate in Frontline AML Trial - citybuzz -
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment - NewMediaWire
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment | Corporate - EQS News
Aptevo Rises on AML Data—But Will It Hold? - Bitget
Aptevo Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
10-K - sec.gov
Aptevo Therapeutics 10-K: Net loss $25.97M, EPS $(87.27) - TradingView
Aptevo Therapeutics (NASDAQ: APVO) outlines bispecific cancer pipeline and AML data - Stock Titan
[8-K] Aptevo Therapeutics Inc. Reports Material Event - Stock Titan
APVO Achieves Significant Advances in Clinical Pipeline and Capi - GuruFocus
Aptevo Provides State of the Business Report and 2025 Financial Results - Bitget
Aptevo (APVO) Strengthens Financial Position for Future Operatio - GuruFocus
No CRS in 28 AML patients as Aptevo adds 3 CD3 drug candidates - Stock Titan
APVO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aptevo Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Aptevo Therapeutics Inc.: Fundamental Analysis and Financial Ratings | AP81 | US03835L5049 - marketscreener.com
APVO Stock Price, Quote & Chart | APTEVO THERAPEUTICS INC (NASDAQ:APVO) - ChartMill
Aptevo Therapeutics Inc.: Fundamental Analysis and Financial Ratings | APVO | US03835L4059 - marketscreener.com
Aptevo to Participate in March 2026 Conferences - ACCESS Newswire
Aptevo sends incoming CEO to Roth, spotlights trispecific drugs in Lisbon - Stock Titan
Hedge Fund Moves: Whats next for Aptevo Therapeutics Inc stock2026 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Aptevo Therapeutics implements 1-for-18 reverse stock split - MSN
Pharma News: Is GeoVax Labs Inc Equity Warrants ROE strong enough2026 Stock Rankings & Weekly High Conviction Ideas - baoquankhu1.vn
Aptevo shares drop despite encouraging AML trial results - MSN
Aptevo’s Mipletamig Shows 86% Clinical Benefit Rate With No CRS in Frontline AML, Promising Safety and Efficacy Data 1 - Minichart
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Aptevo Reports Promising Interim Data for AML Therapy - TipRanks
Aptevo Therapeutics: Mipletamig Shows 86% Clinical Benefit Rate with No CRS in Frontline AML - TradingView
Aptevo Therapeutics Inc Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine - marketscreener.com
Aptevo Therapeutics (APVO) reports 86% benefit, no CRS in mipletamig AML data - Stock Titan
Aptevo Therapeutics (APVO) Reveals Promising Results in AML Tria - GuruFocus
Aptevo Lists Lower on New Developments - Baystreet.ca
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Aptevo Therapeutics stock tumbles despite positive trial data - Investing.com India
Aptevo Therapeutics stock tumbles despite positive trial data By Investing.com - Investing.com UK
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% - Bitget
Leukemia trial: 86% of older patients benefit, no cytokine release syndrome - Stock Titan
Aptevo Therapeutics Stock Rallies On 100% Remission Rate In Acute Myeloid Leukemia Trial Cohort - MSN
Panic Selling: Is Aptevo Therapeutics Inc stock trending bullishQuarterly Investment Review & Daily Price Action Insights - baoquankhu1.vn
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
APVO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aptevo Therapeutics (NASDAQ:APVO) Upgraded at Wall Street Zen - Defense World
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):